SILENCE THER. (SLN)

 

Latest News

Holding(s) in Company

RNS Number: 1357U Silence Therapeutics PLC 19 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Ther...

Holding(s) in Company

RNS Number: 9815T Silence Therapeutics PLC 18 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Silence Thera...

Silence Therapeutics granted US patents

Silence Therapeutics said the US Patent and Trade Mark Office yesterday granted it with two new patents. US patent appli...

Further US patents granted

RNS Number: 8740T Silence Therapeutics PLC 18 October 2017 Further US patents granted 18 October 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Offi...

All News

DateHeadlineSource
19-10-17Holding(s) in CompanyRNS
18-10-17Holding(s) in CompanyRNS
18-10-17Silence Therapeutics granted US patentsStockMarketWire
18-10-17Further US patents grantedRNS
17-10-17Serving of claim in the UK High CourtRNS
16-10-17Silence Therapeutics appoints new chairmanStockMarketWire
16-10-17Appointment of Non-Executive ChairRNS
11-10-17Silence Therapeutics granted US patentStockMarketWire
11-10-17Key US patent grantedRNS
06-10-17Holding(s) in CompanyRNS
28-09-17Holding(s) in CompanyRNS
27-09-17Holding(s) in CompanyRNS
27-09-17Holding(s) in CompanyRNS
26-09-17Holding(s) in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
22-09-17Holding in CompanyRNS
20-09-17Second Price Monitoring ExtnRNS
20-09-17Price Monitoring ExtensionRNS
13-09-17Second Price Monitoring ExtnRNS
13-09-17Price Monitoring ExtensionRNS
11-09-17Silence patents approvedStockMarketWire
11-09-17Further Strengthens US Patent EstateRNS
08-09-17Second Price Monitoring ExtnRNS
08-09-17Price Monitoring ExtensionRNS
06-09-17Silence Therapeutics makes progress on drug pipelineStockMarketWire
06-09-17Interim results for six months ended 30 June 2017RNS
04-09-17Notice of Interim ResultsRNS
23-08-17Save the Date: Capital Markets Event 14 NovemberRNS
17-08-17Replacement - Holding(s) in CompanyRNS
17-08-17Director/PDMR ShareholdingRNS
15-08-17Two further US patents to be grantedRNS
03-08-17Director Deals - Silence Therapeutics PLC (SLN)StockMarketWire
03-08-17Director/PDMR ShareholdingRNS
31-07-17Director Deals - Silence Therapeutics PLC (SLN)StockMarketWire
31-07-17Director/PDMR ShareholdingRNS
31-07-17Silence Therapeutics updates on expansion of its patent estateStockMarketWire
31-07-17Holding(s) in CompanyRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory